Abstract
The recognition of metabolic complications associated with the use of antiretroviral therapy (ART), including dyslipidemia, lipoatrophy, and dysregulation of glucose homeostasis, followed close on the heels of the introduction and widespread use of potent combination ART for the treatment of HIV infection. Our understanding of the role of specific drug classes and of individual antiretroviral agents in these metabolic disturbances has evolved over time and has helped to inform clinical care practices to both preventandtreatthesecomplications.Inthis issue of the Journal, Mallon et al. [1] present data that provide another important step forward in understanding the mechanismsoflipoatrophyinassociation with exposure to nucleoside reversetranscriptase inhibitors (NRTIs) and offer insight into why treatment with the peroxisome proliferator-activated receptor(PPAR)agonistshasoftenfailedto produce clinically significant gains in adipose tissue mass in trials involving HIVassociated lipoatrophy. The potential role of mitochondrial toxicity associated with NRTIs, in particular the potent effects of thymidine analogues (tNRTIs), was recognized early in the study of lipodystrophy and ART tox
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
